OBJECTIVES: To determine if plasma β-amyloid (Aβ) levels (1) can be linked to specific cognitive changes that constitute conversion to Alzheimer disease (AD) and (2) correspond to cognitive change independent of dementia. DESIGN: Longitudinal study including 3 visits during approximately 4¹/₂ years (2000-2006). SETTING: Northern Manhattan community. PARTICIPANTS: Eight hundred eighty individuals from a population-based and ethnically diverse sample who had 2 plasma Aβ measurements and were dementia free at the time of the first Aβ sample; 481 remained cognitively healthy, 329 were cognitively or functionally impaired but not demented at any point, and 70 developed AD. MAIN OUTCOME MEASURES: General estimating equations tested the association between plasma Aβ (baseline and change in values) and cognitive change (composite score and memory, language, and visuospatial indices). RESULTS: High baseline plasma Aβ42 (P = .01) and Aβ40 (P = .01) and decreasing/relatively stable Aβ42 (P = .01) values were associated with faster decline in multiple cognitive domains. In those who remained cognitively healthy, high baseline plasma Aβ42 (P = .01) and decreasing/relatively stable plasma Aβ42 (P = .01) was associated with faster cognitive decline, primarily in memory. CONCLUSIONS: The association between plasma Aβ and multiple aspects of cognition more clearly specifies the previously documented downward trajectory of plasma Aβ with AD onset. The predominant association with memory seen only in healthy elderly individuals also suggests that plasma Aβ is linked with even earlier neurologic changes that may or may not culminate in dementia.
OBJECTIVES: To determine if plasma β-amyloid (Aβ) levels (1) can be linked to specific cognitive changes that constitute conversion to Alzheimer disease (AD) and (2) correspond to cognitive change independent of dementia. DESIGN: Longitudinal study including 3 visits during approximately 4¹/₂ years (2000-2006). SETTING: Northern Manhattan community. PARTICIPANTS: Eight hundred eighty individuals from a population-based and ethnically diverse sample who had 2 plasma Aβ measurements and were dementia free at the time of the first Aβ sample; 481 remained cognitively healthy, 329 were cognitively or functionally impaired but not demented at any point, and 70 developed AD. MAIN OUTCOME MEASURES: General estimating equations tested the association between plasma Aβ (baseline and change in values) and cognitive change (composite score and memory, language, and visuospatial indices). RESULTS: High baseline plasma Aβ42 (P = .01) and Aβ40 (P = .01) and decreasing/relatively stable Aβ42 (P = .01) values were associated with faster decline in multiple cognitive domains. In those who remained cognitively healthy, high baseline plasma Aβ42 (P = .01) and decreasing/relatively stable plasma Aβ42 (P = .01) was associated with faster cognitive decline, primarily in memory. CONCLUSIONS: The association between plasma Aβ and multiple aspects of cognition more clearly specifies the previously documented downward trajectory of plasma Aβ with AD onset. The predominant association with memory seen only in healthy elderly individuals also suggests that plasma Aβ is linked with even earlier neurologic changes that may or may not culminate in dementia.
Authors: E C Mormino; J T Kluth; C M Madison; G D Rabinovici; S L Baker; B L Miller; R A Koeppe; C A Mathis; M W Weiner; W J Jagust Journal: Brain Date: 2008-11-28 Impact factor: 13.501
Authors: Marieke van Oijen; Albert Hofman; Holly D Soares; Peter J Koudstaal; Monique M B Breteler Journal: Lancet Neurol Date: 2006-08 Impact factor: 44.182
Authors: J-C Lambert; S Schraen-Maschke; F Richard; N Fievet; O Rouaud; C Berr; J-F Dartigues; C Tzourio; A Alpérovitch; L Buée; P Amouyel Journal: Neurology Date: 2009-09-15 Impact factor: 9.910
Authors: Nicole Schupf; Ming X Tang; Hide Fukuyama; Jennifer Manly; Howard Andrews; Pankaj Mehta; Jeffery Ravetch; Richard Mayeux Journal: Proc Natl Acad Sci U S A Date: 2008-09-08 Impact factor: 11.205
Authors: Johan Sundelöf; Vilmantas Giedraitis; Michael C Irizarry; Johan Sundström; Erik Ingelsson; Elina Rönnemaa; Johan Arnlöv; Malin Degerman Gunnarsson; Bradley T Hyman; Hans Basun; Martin Ingelsson; Lars Lannfelt; Lena Kilander Journal: Arch Neurol Date: 2008-02
Authors: Clifford R Jack; Val J Lowe; Stephen D Weigand; Heather J Wiste; Matthew L Senjem; David S Knopman; Maria M Shiung; Jeffrey L Gunter; Bradley F Boeve; Bradley J Kemp; Michael Weiner; Ronald C Petersen Journal: Brain Date: 2009-03-31 Impact factor: 13.501
Authors: Jennifer L Bayer-Carter; Pattie S Green; Thomas J Montine; Brian VanFossen; Laura D Baker; G Stennis Watson; Laura M Bonner; Maureen Callaghan; James B Leverenz; Brooke K Walter; Elaine Tsai; Stephen R Plymate; Nadia Postupna; Charles W Wilkinson; Jing Zhang; Johanna Lampe; Steven E Kahn; Suzanne Craft Journal: Arch Neurol Date: 2011-06
Authors: Jon B Toledo; Hugo Vanderstichele; Michal Figurski; Paul S Aisen; Ronald C Petersen; Michael W Weiner; Clifford R Jack; William Jagust; Charles Decarli; Arthur W Toga; Estefanía Toledo; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Leslie M Shaw Journal: Acta Neuropathol Date: 2011-07-30 Impact factor: 17.088
Authors: David J Libon; Mark W Bondi; Catherine C Price; Melissa Lamar; Joel Eppig; Denene M Wambach; Christine Nieves; Lisa Delano-Wood; Tania Giovannetti; Carol Lippa; Anahid Kabasakalian; Stephanie Cosentino; Rod Swenson; Dana L Penney Journal: J Int Neuropsychol Soc Date: 2011-09 Impact factor: 2.892
Authors: S C Burnham; N G Faux; W Wilson; S M Laws; D Ames; J Bedo; A I Bush; J D Doecke; K A Ellis; R Head; G Jones; H Kiiveri; R N Martins; A Rembach; C C Rowe; O Salvado; S L Macaulay; C L Masters; V L Villemagne Journal: Mol Psychiatry Date: 2013-04-30 Impact factor: 15.992
Authors: Fei Song; Anne Poljak; Michael Valenzuela; Richard Mayeux; George A Smythe; Perminder S Sachdev Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Bin Liu; Jeffrey L Frost; Jing Sun; Hongjun Fu; Stephen Grimes; Peter Blackburn; Cynthia A Lemere Journal: J Neurosci Date: 2013-04-17 Impact factor: 6.167